Compare LNT & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LNT | DVA |
|---|---|---|
| Founded | 1917 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Misc Health and Biotechnology Services |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.5B | 15.1B |
| IPO Year | 1999 | 2003 |
| Metric | LNT | DVA |
|---|---|---|
| Price | $77.90 | $233.49 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 4 |
| Target Price | $74.56 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 2.3M | 701.6K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | ★ 16.73 | N/A |
| EPS | 0.87 | ★ 2.87 |
| Revenue | $4,362,000,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $4.61 | $3.85 |
| Revenue Next Year | $6.33 | $3.07 |
| P/E Ratio | $87.97 | ★ $82.14 |
| Revenue Growth | ★ 9.57 | 6.46 |
| 52 Week Low | $60.91 | $101.00 |
| 52 Week High | $78.21 | $238.64 |
| Indicator | LNT | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 63.74 | 78.56 |
| Support Level | $70.41 | $145.58 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.28 | 6.03 |
| MACD | 0.29 | 1.61 |
| Stochastic Oscillator | 84.08 | 78.96 |
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light. Together, IPL and WPL serve nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.